 ATLANTA, GA, and WUHAN, CHINA, Jan. 27, 2020 GLOBE NEWSWIRE -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. GOVXD, a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, together with BravoVax, a vaccine developer in Wuhan, China, today announced the signing of a Letter of Intent to jointly develop a vaccine against the new coronavirus known as 2019-nCoV. Under the collaboration, GeoVax will use its MVA-VLP vaccine platform and expertise to design and construct the vaccine candidate using genetic sequences from the ongoing coronavirus outbreak originating in Wuhan, China. 